$REGN

Regeneron Pharmaceuticals (REGN) has a market cap of $82.3B. Its stock is down 37.1% from its 52-week high but up 37.2% in the past 3 months, outperforming the healthcare sector ETF XLV. Q2 2026 earnings beat expectations with $4.3B revenue and $14.29 adjusted EPS. Analysts have a 'Moderate Buy' consensus with a $852.18 price target, implying 3.4% upside.

McCourt Marion (EVP Commercial) sold 2,346 shares of REGENERON PHARMACEUTICALS, INC. (REGN) at an average of $853.56 ($850.00–$857.39, $2.00M total) across 2 trades over 2026-09-02 to 2026-09-03 under a Rule 10b5-1 trading plan.

Regeneron Pharmaceuticals (REGN) hit a 52-week high of $847.60, up 50.05% over the past year. The stock trades at $847.19, 32% below its InvestingPro Fair Value of $1,118. Q2 2026 earnings were $14.29 per share, with revenue of $4.29 billion, up 17% YoY. Analysts raised price targets, with BofA Securities at $891 and Bernstein SocGen at $756.

U.S. President Trump has secured drug-pricing deals with over 20 pharmaceutical companies, including Pfizer, Johnson & Johnson, and Novo Nordisk, to reduce prescription costs. Agreements involve 'most-favoured-nation' pricing, sales through TrumpRx.gov, and U.S. investment pledges in exchange for tariff relief. Companies like Pfizer and Novo Nordisk have committed to significant price reductions on specific drugs.

Regeneron Pharmaceuticals (REGN) received FDA approval for Pasatru (garetosmab-grts), a new rare disease therapy for fibrodysplasia ossificans progressiva. The drug can be infused at home and showed strong lesion-reduction results. Analysts discuss its impact on Regeneron's investment case, with projections of $19.4B revenue and $6.0B earnings by 2029. Pasatru adds to Regeneron's portfolio but EYLEA's performance remains a key focus.

Regeneron Pharmaceuticals (REGN) received FDA approval for Pasatru to treat adults with fibrodysplasia ossificans progressiva, based on positive Phase 3 trial results. The approval adds a new rare disease therapy to Regeneron's portfolio, potentially diversifying revenue streams. REGN has a market cap of US$80.7b and focuses on immunology and genetic medicine.

The FDA approved Regeneron's (REGN) Pasatru for fibrodysplasia ossificans progressiva, a rare disease. The drug showed a 94% reduction in new bone lesions in a Phase 3 trial. Regeneron's Q2 revenue was $4.29B, up 17%, with strong sales from Dupixent and Eylea HD. Pasatru's market potential is limited due to the disease's rarity, but it validates Regeneron's research platform.

Scotiabank analyst Louise Chen maintained a 'Hold' rating on Regeneron (REGN) with a $770 price target. The mean target is $852.18, suggesting a 2.2% premium, while the highest target is $1,030, implying 23.6% upside.

Regeneron halted its Phase I/IIa TITAN trial for mAb therapy REGN7041 due to safety concerns, according to a filing and company statement. The trial, targeting noninfectious uveitis, enrolled only one patient. Regeneron cited an unfavorable risk-benefit assessment and noted the cause of the safety event remains unidentified.

Veeva Systems announced that Biogen and Regeneron Pharmaceuticals have adopted its Vault CRM platform. The companies will use the AI-driven system for global sales operations, aiming to improve patient access to treatments. Veeva sees this as part of a broader industry shift towards agentic commercial strategies. The deals highlight Veeva's push to migrate customers to its newer Vault CRM architecture. Financial terms and timelines were not disclosed.